InspireMD (NYSE:NSPR) Coverage Initiated by Analysts at Lake Street Capital

Lake Street Capital initiated coverage on shares of InspireMD (NYSE:NSPR) in a research report report published on Wednesday, Marketbeat Ratings reports. The brokerage issued a buy rating and a $5.00 target price on the stock.

A number of other equities analysts have also issued reports on NSPR. Piper Sandler reiterated an “overweight” rating and issued a $4.50 target price on shares of InspireMD in a research report on Tuesday, September 17th. StockNews.com started coverage on shares of InspireMD in a research note on Wednesday, December 4th. They set a “sell” rating on the stock.

InspireMD Trading Down 4.5 %

Shares of NYSE:NSPR opened at $2.95 on Wednesday. The firm’s 50 day moving average is $2.66 and its two-hundred day moving average is $2.68. The firm has a market capitalization of $76.94 million, a P/E ratio of -3.93 and a beta of 0.98. InspireMD has a 52 week low of $1.81 and a 52 week high of $3.42.

InspireMD (NYSE:NSPR) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.16) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.20) by $0.04. InspireMD had a negative return on equity of 69.42% and a negative net margin of 413.96%. The company had revenue of $1.81 million during the quarter, compared to analyst estimates of $1.74 million. During the same quarter in the previous year, the firm posted ($0.15) EPS. Analysts predict that InspireMD will post -0.79 EPS for the current year.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in InspireMD stock. Affiance Financial LLC acquired a new stake in shares of InspireMD, Inc. (NYSE:NSPR) in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 183,746 shares of the company’s stock, valued at approximately $492,000. Affiance Financial LLC owned approximately 0.74% of InspireMD at the end of the most recent quarter. 44.78% of the stock is owned by institutional investors and hedge funds.

InspireMD Company Profile

InspireMD, Inc, a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions.